ArticleHepatitis monthly2015
Economic burden of hepatitis B virus-related diseases: evidence from iran.
Article in Hepatitis monthly, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Acupuncture for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Radix Sophorae flavescentis versus no intervention or placebo for chronic hepatitis B.The Cochrane database of systematic reviews · 2019Pooled it
- Economic burden of hepatitis B patients and its influencing factors in China: a systematic review.Health economics review · 2024Review
- The economic burden of bipolar disorder: a case study in Southern Iran.Cost effectiveness and resource allocation : C/E · 2024Article
- Economic Burden of Hepatitis B at Different Stages of the Disease: A Systematic Review Study.International journal of preventive medicine · 2024Review
- Economic burden of breast cancer: a case of Southern Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- Economic burden of major depressive disorder: a case study in Southern Iran.BMC psychiatry · 2022Article
- Awareness of hepatitis B post-exposure prophylaxis among healthcare providers in Wakiso district, Central Uganda.PloS one · 2022Article
- Article
- Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: a Markov model analysis.Human vaccines & immunotherapeutics · 2021Article
- The economic burden of coronavirus disease 2019 (COVID-19): evidence from Iran.BMC health services research · 2021Article
- Protein-protein interactions of human viruses.Seminars in cell & developmental biology · 2020Review
- Hepatitis B screening and vaccination status of healthcare providers in Wakiso district, Uganda.PloS one · 2020Article
- Determining Breast Cancer Treatment Costs Using the Top Down Cost Approach.European journal of breast health · 2019Article
- Comparative study on guidelines in determining HBV phases in Iranian patients.Gastroenterology and hepatology from bed to bench · 2019Article
- A case-control study of risk factors for hepatitis B infection: A regional report among Isfahanian adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2019Article
- Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers.PloS one · 2019Article
- A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.Hepatitis monthly · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B infection is still the main cause of chronic liver disease in Iran, which is associated with significant economic and social costs.
objectivesThis study aimed to estimate the financial burden caused by CHB infection and its complications in Iran. PATIENTS AND
methodsPrevalence-based and bottom-up approaches were used to collect the data. Data on direct medical costs were extracted from outpatient medical records in a referral gastroenterology and hepatology research center, inpatient medical records in several major hospitals in Tehran and Shiraz in 2013, and the self-reports of specialists. Data on direct non-medical and indirect costs were collected based on the patients' self-reports through face-to-face interviews performed in the mentioned centers. To calculate the indirect costs, friction cost approach was used. To calculate the total cost-of-illness in Iran, the total cost per patient at each stage of the disease was estimated and multiplied by the total number of patients.
resultsThe total annual cost for the activate population of CHB patients and for those receiving treatment at various disease stages were respectively 450 million and 226 million dollars, with 64% and 70% of which allocated to direct costs respectively, and 36% and 30% to indirect costs respectively. The total direct costs alone for each group were respectively 1.17% and 0.6% of the total health expenditure. Furthermore, the cost spent on drugs encompasses the largest proportion of the direct medical cost for all stages of the disease.
conclusionsAccording to the perspectives of payers, patients, and community, CHB infection can be considered as one of the diseases with a substantial economic burden; the disease, specifically in extreme cases, can be too expensive and costly for patients. Therefore, patients should be protected against more severe stages of the disease through proper treatment and early diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.